Free Trial
NASDAQ:BCLI

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

Brainstorm Cell Therapeutics logo
$1.17 -0.03 (-2.50%)
Closing price 04:00 PM Eastern
Extended Trading
$0.67 -0.50 (-42.74%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Brainstorm Cell Therapeutics Stock (NASDAQ:BCLI)

Key Stats

Today's Range
$1.03
$1.28
50-Day Range
$1.06
$1.36
52-Week Range
$0.56
$6.00
Volume
2.54 million shs
Average Volume
413,606 shs
Market Capitalization
$11.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Brainstorm Cell Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
29th Percentile Overall Score

BCLI MarketRank™: 

Brainstorm Cell Therapeutics scored higher than 29% of companies evaluated by MarketBeat, and ranked 819th out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Brainstorm Cell Therapeutics.

  • Earnings Growth

    Earnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($3.01) to ($1.60) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Brainstorm Cell Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Brainstorm Cell Therapeutics is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about Brainstorm Cell Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    7.91% of the float of Brainstorm Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Brainstorm Cell Therapeutics has recently increased by 30.48%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Brainstorm Cell Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Brainstorm Cell Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.91% of the float of Brainstorm Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Brainstorm Cell Therapeutics has recently increased by 30.48%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Brainstorm Cell Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Brainstorm Cell Therapeutics this week, compared to 1 article on an average week.
  • Search Interest

    4 people have searched for BCLI on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    11.15% of the stock of Brainstorm Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.

  • Read more about Brainstorm Cell Therapeutics' insider trading history.
Receive BCLI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Brainstorm Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BCLI Stock News Headlines

I was wrong about Trump
I made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.
Brainstorm Cell Therapeutics Inc. (BCLI) - Yahoo Finance
See More Headlines

BCLI Stock Analysis - Frequently Asked Questions

Brainstorm Cell Therapeutics' stock was trading at $2.27 on January 1st, 2025. Since then, BCLI shares have decreased by 48.5% and is now trading at $1.17.

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) issued its quarterly earnings results on Thursday, May, 15th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by $0.07.
Read the conference call transcript
.

Brainstorm Cell Therapeutics's stock reverse split before market open on Tuesday, October 1st 2024.The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include CocaCola (KO), Organovo (ONVO), Cardium Therapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Protalix BioTherapeutics (PLX) and Isoray (ISR).

Company Calendar

Last Earnings
5/15/2025
Today
7/17/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:BCLI
CIK
1137883
Fax
N/A
Employees
40
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($3.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$11.62 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-519.50%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.21
Quick Ratio
0.21

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($1.36) per share
Price / Book
-0.86

Miscellaneous

Outstanding Shares
9,839,000
Free Float
8,742,000
Market Cap
$11.51 million
Optionable
Optionable
Beta
0.22

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:BCLI) was last updated on 7/17/2025 by MarketBeat.com Staff
From Our Partners